EP Patent

EP3272741A1 — New stable solvate crystalline forms of eluxadoline

Assigned to Archimica SpA · Expires 2018-01-24 · 8y expired

What this patent protects

Two new stable non stoichiomeric crystalline solvate forms of Eluxadoline with 4-methylpentan-2-one or methyl tert -butylether are described as well as the process for the production of the same. The solvate form with 4-methylpentan-2-one is defined as "Eluxadoline form gamm…

USPTO Abstract

Two new stable non stoichiomeric crystalline solvate forms of Eluxadoline with 4-methylpentan-2-one or methyl tert -butylether are described as well as the process for the production of the same. The solvate form with 4-methylpentan-2-one is defined as "Eluxadoline form gamma" whereas the solvate with methyl tert butylether is defined as "Eluxadoline form delta". Form gamma may be obtained by slurrying Eluxadoline amorphous form in 4-methylpentan-2-one; form delta may be obtained by slurrying Eluxadoline form gamma in methyl tert -butylether.

Drugs covered by this patent

Patent Metadata

Patent number
EP3272741A1
Jurisdiction
EP
Classification
—
Expires
2018-01-24
Drug substance claim
No
Drug product claim
No
Assignee
Archimica SpA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.